• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SIBUTRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • SIBUTRAMINE chembl:CHEMBL1419

    Alternate Names:

    REDUCTIL
    SIBUTRAMINE
    BUTRAMIN
    SIBUTRAMINUM
    SIBUTRAMINE HYDROCHLORIDE
    MERIDIA®
    SIBUTRAMINA
    chemidplus:106650-56-0
    drugbank:01105
    chembl:CHEMBL1419
    pubchem.compound:5210
    rxcui:36514

    Drug Info:

    Drug Class appetite depressants
    Year of Approval 1997
    FDA Approval withdrawn
    Drug Class Small Molecule
    Drug Indications appetite suppressant
    (1 More Sources)

    Publications:

    Heusser et al., 2006, Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects., Clin. Pharmacol. Ther.
    Gomis Barbará, [Pharmacological treatment of obesity]., Rev Med Univ Navarra
    Birkenfeld et al., 2005, Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure., Clin. Auton. Res.
    Jordan et al., 2005, Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials., Int J Obes (Lond)
    Birkenfeld et al., 2002, Paradoxical effect of sibutramine on autonomic cardiovascular regulation., Circulation
    Krahn et al., 2001, Narcolepsy and obesity: remission of severe cataplexy with sibutramine., Sleep Med.
    Vazquez Roque et al., 2007, Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine., Clin. Gastroenterol. Hepatol.
    Tziomalos et al., 2009, The use of sibutramine in the management of obesity and related disorders: an update., Vasc Health Risk Manag
    Berke et al., 2000, Medical management of obesity., Am Fam Physician
    Heusser et al., 2007, Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment., J. Clin. Endocrinol. Metab.
    Sharma et al., 2008, Sibutramine: current status as an anti-obesity drug and its future perspectives., Expert Opin Pharmacother
    Nakagawa et al., 2001, Effects of sibutramine on the central dopaminergic system in rodents., Neurotox Res
    Balcioglu et al., 2000, Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid., Neuropharmacology
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Hauner H et al., 2003, Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism., Pharmacogenetics
  • SIBUTRAMINE   SLC6A2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium

    PMIDs:
    16678551 15382615 15944869 15685250 12417543 11152984 11752352 19475780 10929704 17284621 18671470


    Sources:
    TdgClinicalTrial TEND

  • SIBUTRAMINE   SLC6A4

    Interaction Score: 3.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium
    Novel drug target Established target

    PMIDs:
    16678551 15382615 15944869 15685250 12417543 11152984 17544870 19475780 10929704 17284621 18671470


    Sources:
    TdgClinicalTrial TEND

  • SIBUTRAMINE   GNB3

    Interaction Score: 1.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12893983


    Sources:
    PharmGKB

  • SIBUTRAMINE   SLC6A3

    Interaction Score: 1.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium

    PMIDs:
    15382615 15111248 11152984 10974319 19475780 10929704


    Sources:
    TdgClinicalTrial

  • SIBUTRAMINE   CYP3A5

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TEND: SIBUTRAMINE

    • Version: 01-August-2011

    Alternate Names:
    SIBUTRAMINE Primary Drug Name

    Drug Info:
    Year of Approval 1997
    Drug Class appetite depressants

    Publications:

  • TdgClinicalTrial: SIBUTRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications appetite suppressant
    Drug Class Small Molecule
    FDA Approval withdrawn

    Publications:

  • PharmGKB: sibutramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Hauner H et al., 2003, Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism., Pharmacogenetics

  • TTD: Sibutramine

    • Version: 2020.06.01

    Alternate Names:
    D08KVZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1419

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21